New drug combo shows promise for hard-to-treat lymphoma
NCT ID NCT04231448
First seen May 15, 2026 · Last updated May 15, 2026
Summary
This study tested whether adding an oral drug called tucidinostat to standard chemotherapy (R-CHOP) helps people with a fast-growing type of lymphoma called double-expressor DLBCL. The trial involved 423 newly diagnosed adults and measured how long they lived without the cancer getting worse. While the treatment aims to control the disease, patients may still need ongoing monitoring or future therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University Cancer Hospital
Beijing, Beijing Municipality, China
-
Shanghai JiaoTong University School of Medicine，Ruijin Hospital
Shanghai, Shanghai Municipality, China
Conditions
Explore the condition pages connected to this study.